Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26074490 | 0.81 | CD274 (0.50) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL25245334 | 0.80 | JAK2 (0.49) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL18520107 | 0.76 | MAPT (0.45) | RAB9AALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL18520178 | 0.74 | TP53 (0.49) | RAB9ASMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL9980437 | 0.73 | JAK2 (0.39) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL31067541 | 0.73 | MEN1 (0.44) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL17064622 | 0.73 | MEN1 (0.44) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL25415854 | 0.72 | JAK2 (0.53) | CD274JAK2JAK1TYK2JAK3 | |
| SCHEMBL22466151 | 0.71 | BAZ2B (0.50) | RAB9AALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL22128054 | 0.70 | JAK2 (0.48) | CD274JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206197-B1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4206197-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| CN-115996727-A | Process for preparing Rho related protein kinase inhibitors and intermediates in the process | 北京泰德制药股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2022042711-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | 北京泰德制药股份有限公司 | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | ROCK1, ROCK2, ARHGDIA | CD274 4846/4885JAK2 2656/4885JAK1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.